PhytoHealth Corporation announced current R&D progress on PG2, anti-osteoporosis, and moderate to severe pain relief new drugs. Cause of occurrence: 1) In accordance with the provisions on financial statements disclosure, the company makes a public announcement on the R&D progress of the three new drugs currently in development; 2) Concerning new drug R&D stages and workflow from bench to market. As requested by Taiwan Stock Exchange Corporation's letter No.1051801037 issued on Mar.11,2016; 3) New drug under development #1: PG2 Lyophilized Injection: (a) Trial Title: PG2 Treatment for Improving Fatigue among Advanced Cancer Patients under Standard Palliative Care. (b) Institution: Nine medical centers, including MMH, SHH, CGMH-KL, TSGH, CCH, CMH-LY,CMUH, CGMH-LK, and CGMH-KS. (c) Trial Update: The clinical study report has been approved by TFDA. Nine manuscripts based on the clinical study results have been accepted for publication in the renowned medical associations and journals. (D) Clinical trial for treating ischemic stroke: (a) Trial Title: PG2 Injection 500mg for Acute Stroke Study (b) Institution: Fifteen medical centers, including NTUH and CMUH. (c) Trial Update: The study is one of industry-academia collaboration outcomes by CMUH's ”Stroke Clinical Trials and Research Center of Excellence” through ”Industry-Academia Link Innovative Research Office”. The clinical study report has been completed. Currently, the development is planning on subacute ischemic stroke treatment and the draft protocol has been completed. Contract research organizations (CROs) are approached for planning study budgets and timelines. (E) Clinical trial for treating hemorrhagic stroke (a) Trial Title: PG2 Injection 500mg for Spontaneous Intracerebral Hemorrhage Pilot Study. (b) Institution: China Medical University Hospital (c) Trial Update: The study is one of outcomes resulted from the co-established ”Industry-Academia Link Innovative Research Office” with CMU. The results of the clinical trial have been published in a Nature-Series international journal- Scientific Reports. (F) Basic research-related to immune modulating effects of PG2: Two papers were published on International Journal of Medical Sciences and Nutrients earlier this year. (G) Basic research related to suppression of cancer migration and invasion: The paper was published on The American Journal of Chinese Medicine in 2020. 4) New drug in development #2: Anti-oteoporosis Clinical trial for preventing osteoporosis: (a) Trial Title: PH3 for the Prevention of Osteoporosis in Post- menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study (b) Institution: TVGH, CGMH, NTUH and MMH (c) Trial Update: Phase II clinical study was completed. The company continues to assess the compatibility of clinical trial regulations between Taiwan and China and to explore clinical trial cooperation possbility in accordance with clinical trials harmonization. (d) Filed IND annual report to US-FDA on 2020/04/08. (e) The manufacturing process of PH3 is continuously being optimized to fulfill the CMC requirement for larger scale production of PH3. The specifications of PH3 drug product would be maintained to ensure batch to batch consistency and product quality. (f) Continuous monitoring of species identification and cultivation.5) New drug in development #3: Oraphine to treat moderate to severe pain relief Clinical trial of the Oraphine for treating moderate to severe pain: (a) Trial Title: A Randomized, double blind, placebo-controlled, multiple dose study to assess the efficacy, safety and pharmacokinetics of oral nalbuphine, an oral soft capsule, for post-hemorrhoidectomy pain management. (b) Institution: TSGH, TVGH, CHGH, TCGH(Taipei Branch) (c) Clinical trial Update: Pivotal clinical trial was completed and was submitted for GCP inspection. The TFDA approved the GCP inspection of the Oraphine clinical trials on 2019/04/11. The new drug application of the Oraphine 60 mg soft capsule for treating moderate to severe pain is currently under the TFDA had approved process. (a) Three production batches and its analytical method validation are in process. (b) New drug application progress: Received a notification letter with the TFDA’s comments and questions. The response documents were prepared and submitted to TFDA for review on 2019/08/01. Recently, received notification from TFDA for approval of the drug registration license on 2020/04/09. The new drug license of ?Oraphine soft capsule? was awarded on 2020/07/14. (c) Submitted the first issue of the “Regular Safety Report of Drugs” on 2020/11/10. Planning and executing the clinical trial plans for marketing authorization of ”Oraphine 60mg Soft Capsules” in the United States, Japan and Australia.